Savings versus buying the same number of pouches individually at $64.95 each. Up to 30% applies only to the first 8-pouch subscription shipment. Later shipments use the regular subscription price.
Ends Mon Nov 30, 11:59 PM ET (8:59 PM PT).
HEALTHSPANX / THE EVIDENCE CENTER
Browse human studies, reviews and preclinical NMN research. Each record connects the publication to its study design, findings and limitations.
Browse the publication recordsThese are publication records, not a count of independent clinical trials. Human findings, reviews, and preclinical work are distinguished. Supporting literature is not automatically an NMN intervention study.
50 published records
24-week placebo-controlled study in 14 older men with diabetes found NMN tolerable but no significant benefit for grip strength or walking speed.
Meta-analysis of 8 RCTs (342 adults) found no significant pooled benefit of short-term NMN for standard glucose-control or lipid-profile outcomes.
Aged-mouse study found NMN improved endothelial function, arterial stiffness and oxidative-stress measures; translation to human vascular outcomes is unproven.
Preclinical injury-model study linking local NMN accumulation after NMNAT2 loss with axon degeneration; not evidence about routine oral NMN use in people.
Four-week RCT in 31 healthy adults found 1,250 mg/day NMN was well tolerated without severe adverse events or clinically concerning laboratory changes.
Cell/mouse study proposed SLC12A8 as a specific NMN transporter; a later published critique disputed that conclusion.
Cryo-EM structural study resolving how NMN activates SARM1, the enzyme that drives axon degeneration when nerve injury depletes NMNAT2. Uses a nanobody to trap the active state.
60-day RCT of 300 mg/day NMN reported higher NAD+/NADH and some secondary benefits, but post-unblinding participant selection limits interpretation.
Older-men RCT: 250 mg/day NMN increased blood NAD-related metabolites; nominal gait/grip findings were limited by a test-food allocation error.
Single-dose study in 10 healthy men reporting no clinically significant acute changes over five hours and dose-related increases in downstream nicotinamide metabolites.
Twelve-week trial in 36 middle-aged adults: serum nicotinamide increased, while the overall arterial-stiffness difference versus placebo was not significant.
Twelve-week four-group trial in 108 older adults: no significant sleep-quality interaction; drowsiness and sit-to-stand signals were accompanied by placebo improvements.
Post-hoc analysis of the 80-person Yi trial found large interindividual NAD-response variability and exploratory associations with functional outcomes.
Post-hoc analysis of the Yi trial linked blood NAD levels with several laboratory measures; associations are exploratory and not causal treatment effects.
Narrative review of mainly preclinical ocular NMN studies; no human intervention evidence establishes prevention or treatment of ocular disease.
Phase 1/2 single-arm ITP study: 25 patients received 900 mg/day NMN for 2 weeks; safety was favorable and 20% met the primary platelet-response endpoint.
Six-week, four-arm RCT (placebo / 300 / 600 / 1200 mg/day) in 48 amateur runners on ventilatory-threshold and aerobic-capacity measures.
Isotope-tracer study quantified NAD flux and found route-dependent NMN/NR metabolism in mice, with extensive conversion after oral administration.
Landmark 12-month mouse study found NMN altered multiple age-associated physiological and metabolic measures without obvious toxicity in the model.
60-person RCT: primary stepping outcome was null; secondary 4-m walking, blood NAD+ and selected sleep measures favored 250 mg/day NMN.
Single-arm study in 17 postmenopausal women found multiple biomarker changes over 8 weeks; without a control group, causal effects cannot be established.
Four-week randomized overdose-safety trial tested 750 and 1,500 mg/day NMN in 30 healthy adults; it informs short-term tolerability, not efficacy.
High-dose injected NMN improved albuminuria and several renal measures in a mouse injury model; no human intervention was performed.
A small uncontrolled study found that one intravenous NMN dose raised blood NAD+ and lowered triglycerides over five hours, with no acute abnormalities detected.
Narrative review of NMN anti-aging promises and safety concerns, emphasizing strong preclinical interest but sparse human efficacy and long-term safety evidence.
Narrative review of NMN metabolism, uptake, gut microbiome effects, measurement challenges, and person-to-person variability in clinical findings.
In 30 healthy Japanese adults, 250 mg/day NMN for 12 weeks increased whole-blood NAD+ without serious adverse events; clinical metabolic and body-composition outcomes did not significantly change.
28-day RCT in 30 adults: MIB-626 raised NAD+ and showed exploratory cardiometabolic changes; insulin sensitivity and physical performance were null.
Two-week RCT in 32 adults aged 55–80 showing pharmaceutical-grade NMN (MIB-626) at 1,000 mg once or twice daily raised blood NAD⁺ substantially versus placebo with a safety profile matching placebo.
COVID-19/AKI RCT: MIB-626 strongly raised NAD+ but did not significantly improve kidney, inflammation or disease-severity outcomes versus placebo.
Systematic review/meta-analysis found no consistent evidence that NMN improves core skeletal-muscle mass or function outcomes; NMN-specific data were limited.
Translational study with a small human hypertension intervention plus mechanistic models; reported BP/vascular improvements need larger independent confirmation.
Mechanistic cell/mouse study found NRK1 is central to NMN/NR utilization and supported extracellular NMN-to-NR conversion in studied systems.
Perspective summarizing NAD+/NMN mechanisms and advocating liposomal delivery without a direct comparative human trial of that delivery approach.
In a 14-day randomized trial, 1 g/day NMN and NR roughly doubled whole-blood NAD+, while nicotinamide did not; clinical outcomes were not tested.
A narrative review found generally reassuring short-term tolerability but scarce, inconsistent evidence for broad anti-aging effects in humans.
A broad review describes extensive preclinical research but finds human evidence small, short, inconsistent, and insufficient for broad clinical claims.
Injected NMN reduced injury markers and improved later behavior in neonatal mice after experimental hypoxia–ischemia; no human outcomes were studied.
Meta-analysis of 9 NMN trials in middle-aged/older adults found a limited, heterogeneous evidence base for muscle, liver and metabolic outcomes.
Systematic review of 10 RCTs (437 participants) found physical-performance changes were non-significant overall and reported no serious adverse effects.
Open-label study in 11 men: 250 mg/day NMN for 8 weeks increased PBMC NAD+; subgroup metabolic findings were exploratory and uncontrolled.
Mouse cardiac study found NMN increased NAD+ and reduced ischemia/reperfusion injury under experimental conditions; no human cardiovascular efficacy was tested.
Single-arm study in 11 healthy adults: 250 mg/day NMN increased plasma NMN and NAD+ and also raised postprandial insulin, with high variability.
11-man crossover study: NMN dampened some inflammatory signals after BFR exercise but also delayed repair signals and abolished a mitochondrial-content increase.
2026 meta-analysis of 15 RCTs found favorable short-term tolerability but no clear pooled benefit for most metabolic outcomes; long-term safety remains unknown.
80-person dose-ranging RCT: 300–900 mg/day NMN raised blood NAD over 60 days; secondary functional findings were positive while HOMA-IR was null.
Foundational mouse study: NMN restored NAD+ and improved glucose-related metabolic phenotypes in diet- and age-associated diabetes models.
Ten-week trial in 25 postmenopausal women with prediabetes found improved muscle insulin sensitivity, but no change in hepatic insulin sensitivity or body composition.
Systematic review of 12 studies (513 adults) found robust NAD biomarker increases but inconsistent evidence for conventional glucose and lipid benefits.
Meta-analysis of 10 RCTs (349 participants) found no significant overall systolic reduction and a small preliminary diastolic-pressure signal.
Try a broader search, choose another evidence type or reset your filters.
Biomarker findings, self-reported outcomes, and clinical outcomes are not interchangeable. Animal and cellular findings do not establish effects in people. A publication about NMN does not establish equivalence to a HealthspanX product.
Each record keeps the source links and study limitations alongside its interpretation. Report a correction.
